Covovax
- India
Current COVID strain mild, SII producing 5-6million Covovax doses: Adar Poonawalla
Pune: The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company’s chief executive officer…
- India
Serum Institute of India restarts manufacturing of Covishield
New Delhi: Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday said it has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection. He said…
- India
Govt panel recommends Covovax inclusion in vax drive for 12 and above
New Delhi: Covid vaccine Covovax’s inclusion in the vaccination programme for the 12-17 years age group has been recommended by the Covid-19 Working Group, official sources said on Sunday. The Central Drugs…
- India
Corbevax, Covovax, Molnupiravir approved for restricted emergency
New Delhi: Expanding India’s basket of COVID-19 vaccines, the Central Drug Authority has approved Serum Institute of India’s vaccine Covovax, Biological E’s jab Corbevax and anti-Covid pill Molnupiravir for restricted use in…
- India
SEC recommends emergency use authorization of Covovax, Corbevax
New Delhi: After reviewing all applications and data, the Subject Expert Committee (SEC), a body under India’s drug regulator, has recommended granting the Emergency Use Authorization (EUA) to Serum Institute of India’s…
- India
SII starts production of Covovax, CEO says it has ‘great potential’ for children
In a new move towards ensuring better inoculation, the Serum Institute of India (SII) has started the production of the first batch of the Novavax COVID-19 vaccine in India, dubbed Covovax. Novavax…
- World
SII partner Novavax’s COVID-19 shot 90% effective
Washington: US-based biotechnology company Novavax’s protein-based vaccine has shown overall 90 per cent efficacy against Covid-19, results of Phase-3 trials have shown. The vaccine NVX-CoV2373 is already being locally manufactured by the company’s…